MISSING
Act before they’re gone!
Breast cancer research – saving lives
The annual report is available – click hier vinden.
Welcome to BIG’s Annual Report 2022, in which we explore the theme of “MISSING”.
In a world where we have all experienced loss and the absence of loved ones, our determination to reduce the toll of breast cancer is stronger than ever. As one of the most commonly diagnosed cancers worldwide, we remain committed to the dedicated research efforts of BIG’s global network of academic research groups and breast cancer experts. Our mission is to save lives and prevent the heartache caused by the missing of dear ones.
BIG’s annual report showcases the network’s activities and highlights key achievements from the past year. With a special focus on groundbreaking clinical studies like OlympiA, APHINITY, DCIS, POSITIVE, and other vital research conducted by BIG, we present promising results that bring hope. With over two decades of experience, we remain confident in our ability to deliver practice-changing outcomes through innovative, patient-centred research. Our goal is to address critical questions and bridge knowledge gaps.
The section “BIG Philanthropy” provides an overview of activities carried out by BIG against breast cancer, BIG’s dedicated philanthropy unit. It conducts vital fundraising to support BIG’s clinical trials and research programmes that are not driven by commercial interest but hold great significance for breast cancer patients. The funds raised provide the means for BIG member groups and their affiliated hospitals, and other partners to finance their efforts and patient participation in a study. This is made possible through the generosity of foundations, companies, ambassadors, and individuals who contribute to our cause.
For Pink October 2022, we developed a compelling awareness campaign centred around the theme of “MISSING,” honouring the women (and men, in 1% of cases) who are no longer with is to partake in events, celebrations, or group photos. It serves as a poignant reminder that, despite promising medical advances, there is still no sure cure for breast cancer.
In 2022, we achieved significant progress, giving us reason to be optimistic. The worst of the pandemic appears to be behind us, and despite enduring its impact for over two years, the medical field has witnessed positive outcomes. We have embraced new technologies, digital initiatives, and virtual platforms, enabling us to connect and share scientific information effectively. While we have adapted to this new way of working, we have also realised the immense value of in-person interactions and human connection. Through it all, we must remember that at heart of our efforts are real people: us. We’re in this together.
In name of everyone at BIG, we would like to extend our sincere gratitude and appreciation to all member groups, partners, faithful ambassadors, donors and staff for their support and collaborative spirit to help advance breast cancer research. But most importantly, we recognise the invaluable contribution of the tens of thousands of patients who have volunteered to participate in our clinical trials and so are also partners with us to develop the cures of tomorrow. Thank you!
Enjoy the reading.
Professor David Cameron
Voorzitter van BIG
Together, we have the power to transform the face of breast cancer and make a positive impact on the lives of millions
